MedTrace Logo

Ziprasidone vs Standard Therapy for Agitated Patients in the ED

NCT00786318 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2017-09-25

No results posted yet for this study

Summary

The primary objective is to determine if ziprasidone is superior to standard therapies in the emergency department treatment of the acutely agitated patient. The primary outcome will be the length of time taken until the patient is ready to be evaluated by the psychiatric service, or until a disposition is made.

Conditions

Interventions

DRUG

ziprasidone

ziprasidone 20mg IM

DRUG

Standard therapy

Haldol 5mg/ Ativan 2mg IM

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • George Washington University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2011-07-31
Completion
2011-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00786318 on ClinicalTrials.gov